Research programme: motilin receptor antagonists - Ocera Therapeutics

Drug Profile

Research programme: motilin receptor antagonists - Ocera Therapeutics

Alternative Names: TZP-201; TZP-202

Latest Information Update: 17 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tranzyme
  • Developer Ocera Therapeutics; Tranzyme
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Motilin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diarrhoea; Gastrointestinal disorders
  • Discontinued Non-ulcer dyspepsia

Most Recent Events

  • 15 Jul 2013 Ocera Therapeutics has completed its merger with Tranzyme Pharma
  • 29 Mar 2012 Preclinical development is ongoing in USA
  • 29 Mar 2012 Research programme: motilin receptor antagonists - Tranzyme is available for licensing as of 29 Mar 2012. http://www.tranzyme.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top